Novel treatment strategies are needed for chronic lymphocytic leukemia (CLL) because current approaches can alleviate symptoms but are not curative. 1 One approach is suggested by the existence of immunogenic death, a differentiation process that is mediated by sustained activation of stress signaling pathways and culminates in either cell death or a state of heightened sensitivity to cytotoxic T cells and drugs. 2, 3 Agents that force CLL cells into an immunogenic death pathway might improve clinical outcomes by eliminating the cells directly, enhancing the efficacy of conventional chemotherapy, or facilitating killing of cytotoxic T cells through increased tumor immunogenicity. Toll-like receptor (TLR)-7 agonists are potentially targeted immunogenic death agents for CLL. 4 ,5 CLL cells express TLR-7, which has a limited tissue distribution otherwise, 5 and are killed directly, or sensitized to cytotoxic lymphocytes and drugs (particularly the microtubule inhibitor, vincristine), by imidazoquinoline TLR-7 agonists such as 852A in vitro. 4 Moreover, cutaneous CLL infiltrates are cleared by topical application of TLR-7 agonists. 5 Therefore, we analyzed the ability of intravenous injections of 852A to clear systemic disease in patients with relapsed CLL in the context of a phase I/II trial approved by both Health Canada and the Sunnybrook Research Ethics Board.
Patients recruited from the CLL clinic at Sunnybrook were eligible if they gave informed consent, required treatment for CLL based on NCI guidelines, 1 had received at least two previous courses of chemotherapy, including fludarabine, and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Active treatment for CLL within the earlier 4 weeks, other uncontrolled medical conditions, a hemoglobin level o80 g/l, platelet levelo60 000/ml, or a second malignant condition, such as Richter's transformation, were the exclusion criteria.
The study used a modified standard 3 Â 3 dose escalation design, with cohort numbers increased from 3 to 5 to allow collection of more data on the biological effects of 852A, while limiting drug exposure to as few patients as possible. Three groups of five patients were injected with 852A (3M Pharmaceuticals, St Paul, MN, USA) 6,7 twice weekly for 5 weeks at the Sunnybrook Chemotherapy Suite. Patients in groups I, II and III were injected with 0.3, 0.45 and 0.6 mg/m 2 , respectively, because studies of solid tumor patients had established 1.2 mg/m 2 as the maximum tolerated dose for 852A. 7 Clinical responses were determined by standard National Cancer Institute (NCI) criteria.
1 Blood was also taken before, and 4 h after, the first infusion of each week for flow cytometric analysis and measurement of cytokines. Serum immunoglobulins (Igs) were measured at the beginning and end of the trial by the Clinical Hematology Laboratory at Sunnybrook. Clinical characteristics of the patients are shown in Table 1 and indicate an extensively pretreated high-risk population with advanced stage disease and unfavorable prognostic features (including chromosome 17 or 11 deletions). 1 Treatments began on 30 January 2006 and were completed on 26 October 2007. The study was closed after the fourth patient in group 3 because the end points (that is, toxicity and response rate) had been reached. No patient was removed from the trial because of toxicity or disease progression.
852A was generally well tolerated and the dosing schedule was not altered for any patient. In contrast to the experience with solid tumor patients at similar doses, 6, 7 no grade 3 toxicities were seen. Adverse effects reported most frequently were chills and 'hot flashes', which seemed to decrease with repeated injections. In some patients, fatigue developed toward the end of the treatments, but it was not clear whether this was related to the underlying disease.
Changes in circulating white blood cell counts (reflective of tumor burden) during the course of the trial are shown in Figure 1 for each patient. No patient met the criteria for a partial or complete response (CR). 1 An increase in the number of blood lymphocytes by 50% or more (indicative of progressive disease 1 ) occurred in three patients (patients 104, 203 and 302), who died shortly after completing the trial but who had also progressed through their earlier chemotherapies. Patient 303 remains clinically free of disease more than a year after completing 852A injections without other treatment. However, the other patients required additional therapy (Table 1) .
Given the continued therapeutic need of many of the patients, a vincristine-containing regimen was administered to 9 out of 14 patients within 3 days of their final injection of 852A. The rationale for this choice was based on in vitro evidence that TLR-7 agonists particularly sensitized CLL cells to vincristine compared with fludarabine. 4 Patient 103 achieved a temporary Letters to the Editor 50% response to the vincristine-containing chemotherapy regimen, cyclophoshamide, vincristine, prednisone (CVP), 8 to which he had earlier been refractory (Figure 1) , which is perhaps consistent with chemo-sensitization by 852A. However, eight other patients treated in a similar manner, including two whose tumor cells had 17p deletions, did not show this chemosensitizing effect (Figure 1) .
Chronic lymphocytic leukemia cells increase their surface expression of co-stimulatory molecules and produce cytokines (such as tumor necrosis factor a) within several hours of being activated through TLR-7 in vitro. 4 No significant changes in expression of a panel of B-cell activation markers on CLL cells analyzed 4 h after the first injection of 852A of the week were noted (not shown). However, serum levels of a number of cytokines, particularly tumor necrosis factor-a, interleukin-6 and interferon-a, increased in some patients after 852A infusions (Figures 2a-c) , without an obvious relationship to dose of 852A or week of injection. Patient 103 was the only group 1 patient who showed increased circulating tumor necrosis factor-a levels after treatment with 852A ( Figure 2a, week 2) . Interestingly, this patient was also the only one whose tumor cells appeared to have been sensitized to vincristine-based chemotherapy after exposure to 852A in vivo (Figure 1; patient 103) .
Toll-like receptor-agonists cause Ig production by stimulating B cells directly or indirectly through the induction of factors such as interleukin-6. Total serum IgG and IgA levels did not change after completion of 852A injections, but IgM levels increased significantly by an average of 0.05 ± 0.02 g/l (Po0.05) in seven patients (Figure 2d ). Although it is unclear whether the increase was polyclonal (and originated in residual normal B cells) or monoclonal (and of CLL origin), the result is consistent with biological activity of 852A in vivo.
Taken together, the results suggest that the TLR-7 agonist, 852A, can be given safely to CLL patients at doses of at least The cytokine and antibody production in response to TLR-7 activation in vivo. Serum levels of tumor necrosis factor (TNF)-a, interleukin (IL)-6 and interferon (IFN)-a were measured before and 4 h after the first injection of 852A of the week. For patients in groups 1 (a) and 2 (b), the levels were measured as part of a multianalyte fluorescent bead assay as described earlier. 4 For patients in group 3 (c), cytokines were measured by individual enzyme-linked immunosorbent assay (ELISA), were not available for patient 304 and did not include interferon-a. Results for each individual patient sample are shown. (d) Serum immunoglobulin (Ig) levels for seven patients were measured 1 month before, and 1 month after, the 852A injection schedule. These levels were not measured in patients 102, 103, 204 and 205, and patients 101, 203 and 304 were receiving replacement g-globulin for disease-related antibody deficiencies. Total IgM levels (but not IgG and IgA) were found to increase significantly after treatment with 852A.
Letters to the Editor 0.6 mg/m 2 and leads to the production of inflammatory cytokines (Figures 2a-c) and IgM (Figure 2d ). In one patient (patient 103), previous exposure to 852A appeared to make drug-resistant tumor cells temporarily more sensitive to a vincristine-based chemotherapy regimen (Figure 1 ), supporting a possible chemo-sensitizing role for TLR-7 agonists in vivo. 4, 5 Despite these encouraging observations, 852A had only weak clinical efficacy on its own, which was disappointing in view of the expectations raised by the preliminary in vitro observations and activity of TLR-7 agonists against cutaneous CLL.
3,5
The magnitude of side effects observed in CLL patients were less severe than reported in solid tumor patients treated with similar doses of 852A. 6, 7 It is possible that the dosing or injection schedule, which was based on the solid tumor trials, was not appropriate for CLL patients. The number of TLR-7 þ targets would be much larger in CLL patients, whose tumor cells express TLR-7, unlike solid tumors. 5 Accordingly, the amount of 852A encountered by each target CLL cell might be much lower than the amount encountered by target cells in solid tumor patients. Potentially, higher and more frequent doses of 852A may be needed for CLL patients, especially those with very high circulating lymphocyte counts.
Other explanations for the lower toxicity of 852A in this trial might be the immunodeficient state of CLL patients, 1 which could impair inflammatory cytokine production, or the aggressive nature of the tumor cells in the patient population. However, TLR-7 agonists appeared to be especially active against more clinically aggressive CLL cells in vitro.
9 Therefore, besides the technical issues of appropriate dosing and scheduling, certain characteristics of the disease, which are unrelated to the tumor cells themselves, may be preventing TLR-7 agonists from achieving their apparent potential as immunotherapeutic agents for CLL. One possibility is that microenvironmental factors, such as hypoxia, prevent strong TLR-7-mediated stimulation of CLL cells in vivo. 3 We have recently found that CLL cells treated with TLR-7 agonists in hypoxic conditions in vitro do not become sensitized to cytotoxic agents (not shown). Strategies to increase microenvironmental oxygen tension (such as hyperbaric oxygen) might then significantly improve the clinical efficacy of TLR-7 agonists.
The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis The BCR-ABL tyrosine kinase is central to the pathogenesis of chronic myeloid leukemia (CML) and Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). Depending on the breakpoint in BCR, several BCR-ABL variants can be generated (Figure 1a) , such as p190 BCR-ABL and p210 BCR-ABL , which are detected in the majority of cases of Ph-positive ALL and CML, respectively. 1 The p190 BCR-ABL isoform was previously reported to show elevated tyrosine kinase activity, 2, 3 although the structural basis for increased kinase activity has not
